DOYLESTOWN, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical…
On track to present initial data from Phase 1/2 clinical trial of MRT-2359 for MYC-driven solid tumors in the second…
- Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or metastatic solid tumors; initial first-in-human…
HOOKIPA reported positive preliminary Phase 2 data on HB-200 in combination with pembrolizumab in 1st-line setting for advanced head and…
NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion regimenNKX019 clinical data presented at…
BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and…
The conference invites executives and clinicians to collaborate and help shape a new era in healthcare.CANTON, Mass.--(BUSINESS WIRE)--MEDITECH will be…
Funding for Phase 1, 2, and 3 trials sought to develop NP-300 to increase American preparedness and response time in…
Cutting-edge AI/machine learning technology with validation in humans for early diagnosis of lung cancer In silico detection for 12 additional…
Management will present and hold virtual 1-on-1 meetings with institutional investors and analystsCompany recently announced license and collaboration expansions for…